Heres what we know and dont know: Most cases were described as mild and did not lead to stopping the drug Its not seen with semaglutide or tirzepatide it may be related to glucagon receptor activation, but this isnt confirmed The Phase 2 trial did note altered or enhanced skin sensation at lower rates, so it may not be entirely new just more apparent at scale It needs investigation across the remaining 7 Phase 3 trials reporting in 2026 Is it a dealbreaker

Ideal candidates include: Adults over 30 seeking to improve body composition despite consistent exercise and nutrition Athletes and active adults looking to accelerate recovery and reduce injury downtime Patients experiencing poor sleep quality unresponsive to standard interventions Adults interested in anti aging benefits including skin, hair, and energy improvements Individuals who want growth hormone support without the cost and risks of direct HGH therapy Candidates should have baseline blood work showing declining IGF 1 levels and no contraindications to growth hormone stimulation
Latin America Market Insights The Latin American market growth is supported by the rising influence of mobile health clinics in underserved regions
Sources: Newsome, Philip N., et al
DOI:10.1007/s00702-014-1180-8 [4]Minich, Deanna M, and Benjamin I Brown